Business Wire

New Report Highlights That the Czech Republic Could Serve as a Model for the EU in Addressing Smoking Prevalence

10.6.2022 07:00:00 EEST | Business Wire | Press release

Share

Ahead of the start of the Czech Presidency of the Council of the EU in July, the think tank Centre for Economic and Market Analysis (CETA) published the comparative study “A new approach towards tobacco legislation: the case for harm reduction in CEE and the EU” at an event in Prague. It presents a new measure, the so-called ‘Harm Reduction Index’ which ranks EU Member States according to their ability to implement the concept of risk reduction.

Yesterday, an event organised by the Czech think tank Centre for Economic and Market Analysis (CETA) brought together medical and addiction experts in Prague to discuss how a tobacco-free generation, where less than 5% of EU-citizens use tobacco, can be achieved by 2040. They concluded that the objectives laid out in Europe’s Beating Cancer Plan cannot be attained under current circumstances and that a revised tobacco control policy based on scientific evidence is needed.

"If the European Commission is serious about its plans to reduce the number of smokers and the impact of smoking, it must start considering the concept of risk reduction in the area of smoking,” Czech National Drug Coordinator Mgr. Jindřich Vobořil highlighted at the event. “The Czech Government has committed itself to this approach in its programme statement for the upcoming Presidency. I will also promote it in relation to the ongoing evaluation of the Tobacco Products Directive, which is an effective policy to achieve a real reduction in the number of smokers of conventional cigarettes,” he added.

"The data show that the abstinence approach is inadequate. The solution for smokers is to switch to less harmful alternatives," agreed Assoc. Ernest Groman, MD, from the Vienna Nicotine Institute. The only European country close to the 5% target is Sweden. According to the experts, the low number of smokers is mainly due to the availability of less harmful alternatives.

Assoc. MUDr. Viktor Mravčík, Ph.D added that, "The harm reduction approach should be implemented by the European Commission in the context of Europe’s Beating Cancer Plan and the revision of the Tobacco Products Directive.”

"According to the Harm Reduction Index, the Czech Republic ranks second among the countries compared. The Czech government should use the upcoming Presidency to undertake a comprehensive review of tobacco dependence policies based on science rather than emotion,” CETA Research Director Ing. Aleš Rod, Ph. D. and member of the Advisory Board to the Czech Government concluded.

About CETA:

The Centre for Economic and Market Analysis (CETA) is a non-governmental, non-profit organisation that aims to analyse market, socio-economic and political phenomena and highlight their impacts.

The Institute for Rational Addiction Policies is a multidisciplinary association of independent and distinguished experts who are dedicated to research and education in the field of addiction from all perspectives.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Aleš Rod
ales.rod@eceta.cz

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough7.7.2026 16:00:00 EEST | Press release

Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical reporting into nonclinical workflows, marking a significant step forward in accelerating drug development timelines. Building on proven results in clinical reporting, where the collaboration has achieved up to first-draft clinical study reports (CSRs), the teams have now successfully applied similar AI capabilities to nonclinical data through high-quality parsing of raw and SEND datasets in a proof-of-concept. This advancement aligns with the Altasciences Acceleration Platform, designed to fast-track drug development across the early-phase development continuum. “This milestone reflects the power of in

Gurobi Launches Intelligence Hub to Deliver AI-Guided Workflows Across the Optimization Lifecycle7.7.2026 16:00:00 EEST | Press release

Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the launch of the Gurobi Intelligence Hub, the new home for Gurobi’s AI-powered optimization agents. The Intelligence Hub is designed to help users build, understand, troubleshoot, and interact with optimization models more effectively. Together, the Hub’s specialized agents leverage generative AI to guide users through workflows across the optimization lifecycle, creating new opportunities to make optimization more accessible, intuitive, and valuable for a broader range of users. The Modeler combines guided workflows with Gurobi’s optimization expertise to help users move from business problem to production-quality optimization model. Through an iterative process that helps refine requirements, validate assumptions, and develop acceptance tests, the Modeler gives users confidence that their model accurately reflects the intended business problem.The Explainer helps users interpret model instances

SS&C Expands Tokenized Investment Capabilities with Digital Cash Settlement7.7.2026 16:00:00 EEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced plans to enable digital cash settlement for tokenized investment transactions using regulated forms of digital cash, including stablecoins and tokenized commercial bank deposits. The announcement builds on the successful launch of SS&C's live tokenized fund issuance and distribution capabilities earlier this year following the acquisition of Calastone in 2025. SS&C already enables asset managers to bring tokenized versions of traditional investment funds to market through the infrastructure and connectivity they already use, helping bridge traditional and digital investment markets. As interest in tokenized investment products continues to grow, the market is increasingly looking beyond tokenization towards the infrastructure needed to support digital transactions. Having already enabled the issuance and distribution of tokenized funds, SS&C is now extending its innovation roadmap to support the next stage of the digital i

Quaise Energy Raises $134 Million in Initial Close of Series B to Build World’s First Superhot Geothermal Power Plant7.7.2026 15:01:00 EEST | Press release

Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced the first close of its Series B financing, raising $134 million with additional equity and debt capital expected to close imminently. The round was led by Prelude Ventures, with strategic investments from JERA and Idemitsu, two of Japan's largest energy companies. Nearly all existing investors, including Safar Partners, participated in the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707844187/en/ The proceeds from Series B will fund Project Obsidian, the world’s first commercial superhot geothermal power plant, and the continued development and commercialization of Quaise's millimeter wave drilling system towards depths in excess of 5 km. Project-level equity and debt financing is concurrently being raised as the company advances toward first revenues secured by yet-undisclosed commercial off-take partners. The Series

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development7.7.2026 15:00:00 EEST | Press release

Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk of light-chain mispairing and providing a robust molecular foundation for subsequent BsADC development. By bringing together the complementary capabilities of Biocytogen and Whitehawk, the collaboration aims to identify BsADC candidates with differentiated targeting profiles and therapeutic potential. “W

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye